CAPR News - Candlesense

CAPR Stock News: Investors with Large Losses Should Contact Robbins LLP to Learn About Leading the Capricor Therapeutics, Inc. Class Action Lawsuit

SAN DIEGO, Aug. 12, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDA...

What is the potential impact on CAPR's future financing needs, including equity raises or debt financing, given the added legal risk? How are institutional investors and major shareholders reacting to the filing—are there any notable changes in holdings or sentiment? Could the lawsuit lead to a recall of any products, termination of collaborations, or other operational disruptions?

Lawsuits

8 days ago

Read more prnewswire

Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today a...

Are there any regulatory or FDA milestones anticipated in the near term that could drive the stock price? What is the expected impact of operating expense trends on profitability and breakeven timelines? How might the low sentiment score (20) influence market perception, and is there evidence of a potential short‑term price correction?

Earnings

9 days ago

Investors in Capricor Therapeutics, Inc. Should Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights - CAPR

NEW YORK, Aug. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR). Shareholders who purchased shares of CAPR durin...

What steps, if any, is management taking to mitigate the impact of this lawsuit on shareholders and the market? What are the potential long‑term implications for the company’s valuation and strategic plans if the case proceeds to litigation? Are there any comparable cases in the sector and what was their effect on the involved companies’ stock performance?

Lawsuits

9 days ago

Read more prnewswire

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, Aug. 11, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capr...

How will this news affect CAPR's stock volatility and options pricing (implied volatility)? What are the comparable impacts of similar securities fraud cases on competitors' stock prices? How might the case influence the upcoming earnings report and guidance?

Lawsuits

9 days ago

Read more prnewswire

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit

NEW YORK, Aug. 8, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024...

How might the outcome of the lawsuit influence analyst coverage and earnings forecasts for CAPR? Is there any indication that the lawsuit could lead to a restatement of financial results or disclosures? What steps can investors take to protect their positions or hedge exposure to CAPR amid this legal risk?

Lawsuits

11 days ago

Read more prnewswire

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Capricor To Contact Him Directly To Discuss Their Options If you purchased or acqu...

Does the lawsuit create any regulatory or compliance risks that could affect future product approvals? What is the expected impact on volatility and option pricing for CAPR options? How will the market's perception of corporate governance at Capricor change after this disclosure?

Lawsuits

12 days ago

Read more prnewswire

Class Action Filed Against Capricor Therapeutics, Inc. (CAPR) Seeking Recovery for Investors - Contact Levi & Korsinsky

NEW YORK, Aug. 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit. CLA...

Will this legal development affect any pending M&A or partnership discussions for CAPR? What are the potential effects on existing shareholder positions and potential short‑selling opportunities? How might this lawsuit influence the valuation multiples (e.g., P/E, P/S) applied to CAPR?

Lawsuits

12 days ago

Read more prnewswire

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

– Second Quarter 2025 Financial Results and Corporate Update Rescheduled to Monday, August 11, 2025, at 4:30 p.m. ET – – Second Quarter 2025 Financial Results and Corporate Update Rescheduled to M...

Are there any regulatory or clinical risks highlighted in the upcoming corporate update that could affect long‑term valuation? What milestones or catalysts are scheduled after the Type A meeting that could further influence the stock? How will the results of the Type A meeting impact Capricor’s cash burn, runway, and need for additional financing?

Earnings

12 days ago

Investors in Capricor Therapeutics, Inc. Should Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights - CAPR

NEW YORK, Aug. 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR). Shareholders who purchased shares of CAPR during...

How should the current position be adjusted—should we reduce exposure, hedge, or maintain the position pending further developments? Will the lawsuit trigger any regulatory reviews or disclosures that could further impact the stock? Are there any precedent cases involving similar biotech firms that could inform the likely outcome?

Lawsuits

13 days ago

Read more prnewswire

Kirby McInerney LLP Reminds Capricor Therapeutics, Inc. (CAPR) Investors of Class Action Filing and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)---- $CAPR #CAPR--The law firm of Kirby McInerney LLP reminds investors who purchased Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ:CAPR) securities to ...

Are there any insider trading or insider selling patterns emerging following the notice? What potential impact could this have on CAPR’s ability to raise capital or secure financing? How does the risk profile from this lawsuit compare to similar biotech companies facing similar litigation?

Lawsuits

14 days ago